Jascayd®

Drug - Jascayd® (nerandomilast) [Boehringer Ingelheim Pharmaceuticals, Inc.]

August 2026

Therapeutic Area - Pulmonary fibrosis

Initial approval criteria

Patient must meet an age-appropriate medically accepted indication, as defined in Section 1927 of the Social Security Act, for the requested agent; AND
Diagnosis of idiopathic pulmonary fibrosis (IPF) confirmed by lung biopsy OR high-resolution computed tomography; OR
Diagnosis of progressive pulmonary fibrosis (PPF) consistent with current, established guidelines; AND
Documented pulmonary function test within the past 60 days reflecting Forced Vital Capacity (FVC) ≥45% of predicted AND;
Patient baseline carbon monoxide diffusing capacity (DLCO, corrected for hemoglobin) ≥25% of predicted AND;
Prescriber is a specialist in the area of the patient’s diagnosis (e.g., pathologist, pulmonologist, radiologist, rheumatologist) or the prescriber has consulted with a specialist in the area of the patient’s diagnosis; AND
Prescriber has reviewed Jascayd Drug Interactions and will monitor patient status as appropriate.

Patient must continue to meet the above criteria; AND
Patient must have clinical benefit (e.g., reduction in forced vital capacity [FVC] decline); AND
Patient has not experienced any treatment-restricting adverse effects.

Provider Call Center (844) 575-7887